Subjects on Dupilumab for Insulin Resistance

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Mayo Clinic Arizona, Scottsdale, AZ
Insulin Resistance+4 More
Dupilumab - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this study is to better understand the interactions between the innate immune system, in particular eosinophils, their secreted cytokines (interleukin-4), and metabolism in human health and disease states such as obesity and insulin resistance.

Eligible Conditions

  • Insulin Resistance
  • Dermatitis, Dermatitis Atopic

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Insulin Resistance

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: baseline

baseline
Adipo-IR
Adipokines
Fasting Free Fatty Acid
Homa IR
Matsuda Index
Systemic inflammatory markers

Trial Safety

Safety Progress

1 of 3

Other trials for Insulin Resistance

Side Effects for

Dupilumab 300 mg Q4W
19%Dermatitis atopic
12%Nasopharyngitis
8%Upper respiratory tract infection
6%Pharyngitis streptococcal
5%Headache
0%Influenza
0%Appendicitis
This histogram enumerates side effects from a completed 2018 Phase 3 trial (NCT03054428) in the Dupilumab 300 mg Q4W ARM group. Side effects include: Dermatitis atopic with 19%, Nasopharyngitis with 12%, Upper respiratory tract infection with 8%, Pharyngitis streptococcal with 6%, Headache with 5%.

Trial Design

2 Treatment Groups

Subjects on Phototherapy
1 of 2
Subjects on Dupilumab
1 of 2
Active Control
Experimental Treatment

24 Total Participants · 2 Treatment Groups

Primary Treatment: Subjects on Dupilumab · No Placebo Group · Phase < 1

Subjects on Dupilumab
Drug
Experimental Group · 1 Intervention: Dupilumab · Intervention Types: Drug
Subjects on Phototherapy
Other
ActiveComparator Group · 1 Intervention: Photo therapy · Intervention Types: Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dupilumab
2017
Completed Phase 3
~9450

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline

Trial Background

Elena Anna (Eleanna) De Filippis M.D., Ph.D., Principal Investigator
Principal Investigator
Mayo Clinic
Closest Location: Mayo Clinic Arizona · Scottsdale, AZ
Photo of mayo clinic arizona  1Photo of mayo clinic arizona  2Photo of mayo clinic arizona  3
2005First Recorded Clinical Trial
1 TrialsResearching Insulin Resistance
147 CompletedClinical Trials

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
BMI > 30 kg/m^2.
You have a diagnosis of Atopic Dermatitis.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.